Back to search

Article

Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Plus Thoracic Radiotherapy Improves Survival in Patients with Epidermal Growth Factor Receptor-Mutated Stage IV Non-Small Cell Lung Cancer

2024-12-02

Abstract excerpt

<title>Abstract</title> <p>Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent a front-line therapeutic regimen for patients with EGFR-mutated stage IV non-small cell lung cancer (NSCLC). Our study aimed to provide the first comparative assessment of the value of third-generation EGFR-TKIs and thoracic radiotherapy (TRT) with TKI alone. Methods We retrospectively colle...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
02776e28-2d20-5b9a-92e0-df6628c77743
DOI
10.21203/rs.3.rs-5388667/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Plus Thoracic Radiotherapy Improves Survival in Patients with Epidermal Growth Factor Receptor-Mutated Stage IV Non-Small Cell Lung CancerDOI 10.21203/rs.3.rs-5388667/v1
Thoracic radiotherapy synergizes with first-line EGFR-TKIs in advanced EGFR-mutant NSCLC: A dual-center real-world study.Semantic proximity
Radiotherapy combined with EGFR-TKIs for stage III EGFR-Mutated lung cancer: A retrospective cohort studySemantic proximity
Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial.Semantic proximity
Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors.Semantic proximity
Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.Semantic proximity
Third-Generation EGFR-TKIs Combined With Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Real-World Study.Semantic proximity
Prognostic implications of combining EGFR-TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19-Del or 21-L858R mutations: A real-world study.Semantic proximity
Thoracic Radiotherapy and Radiation Time Would Affect the Efficacy of Advanced Non-Small Cell Lung Cancer for Patients Who Responded to TKIs Treatment.Semantic proximity
Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study.Semantic proximity
FIN-EGFRprint: a Finnish real-world study on treatments and outcomes in advanced NSCLC with common EGFR mutations.Semantic proximity
Impact of EGFR Mutation Subtypes and TKI Generations on Clinical Outcomes in Lung Adenocarcinoma Patients with Brain Metastases Treated with Gamma Knife RadiosurgerySemantic proximity
Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trialSemantic proximity
Select a neighboring publication to make it the new centre.